Drawing on the searches we run, this lays out what actually separates the candidates who get these roles from those who do not. Approval experience is among the most valuable things a pharmaceutical professional can show, and it is routinely presented in a way that tells a reader almost nothing. Naming an approved product establishes that you were present; describing what you contributed, what went wrong, and what you decided establishes that you were consequential.
Key Takeaways
- Naming an approved product shows presence, not contribution.
- Specify your role, the pathway, and the timeline.
- Describe difficulties encountered, not only the approval.
- Show judgment through decisions you influenced.
- Include work on programmes that were not approved.
Presence Versus Contribution
A resume line stating involvement in the approval of a named product invites a reader to imagine a contribution that may or may not have existed. Approvals involve dozens or hundreds of people over years, and readers assessing pharmaceutical candidates know this, so they discount unspecified association heavily. What converts the credential into evidence is specificity: which submission, which components you owned, which agency interactions you led or attended, what you personally produced, and what decisions you influenced. That specificity survives reference checking, which vague association does not.
Give the Reader the Shape of the Programme
Useful context includes the pathway, the therapeutic area, the phase or stage you joined, the timeline from filing to approval, whether there were major objections or an extended review, and whether the programme was straightforward or contested. Two candidates can both list an approval where one navigated a complete response and a substantial redesign while the other joined after filing. The shape of the programme tells a reader how much judgment the work required, and candidates who omit it are usually leaving their strongest evidence unstated.
Difficulties Are More Informative Than Successes
Approvals that proceeded smoothly demonstrate competent execution; approvals that survived a major objection, an advisory committee, an inspection finding, or a required additional study demonstrate judgment under pressure. If you worked through difficulty, describe it: what the problem was, what you recommended, what happened. Readers assessing senior candidates are looking for evidence of judgment when the path was unclear, and difficulties are where that evidence lives. Presenting only the clean outcome discards it.
Do Not Omit Programmes That Failed
Candidates frequently exclude programmes that were terminated, refused, or withdrawn, treating them as blemishes. This is usually a mistake. Pharmaceutical careers contain failures, experienced readers expect to see them, and how you handled one is informative. A well-described account of a programme that failed, what the evidence showed, what you recommended, how the decision was made, often reads more credibly than an unbroken record of approvals, which can suggest either a short career or selective presentation.
What This Looks Like in Practice
A candidate presents approval experience by specifying the submission, their owned components, agency interactions they led, the pathway and timeline, and the difficulties encountered, including describing programmes that failed and what they recommended, so that a reader can assess contribution rather than infer it.
The Mistake Candidates Keep Making
The most common mistake is listing approved products as credentials without describing contribution, on the assumption that association with a successful approval speaks for itself. Readers discount unspecified association because approvals involve large teams, so the candidate’s strongest experience conveys less than a specific account of a smaller contribution would have.
Weak Approval Claims vs Strong
| Weak | Strong |
|---|---|
| Involved in approval of Product X | Owned CMC sections of the Product X submission |
| Supported regulatory submissions | Led two agency meetings securing agreement on endpoints |
| Contributed to successful filing | Managed the response to a major objection on comparability |
| Multiple approvals across TAs | Named pathways, timelines, and what each required |
| No mention of failed programmes | An account of a terminated programme and your recommendation |
The Bottom Line
Approval experience becomes persuasive only when you specify what you owned, which agency interactions you led, the pathway and timeline, and the difficulties navigated, and including programmes that failed usually strengthens rather than weakens how a senior reader assesses you. Be deliberate about this, and you will be choosing between offers rather than hoping for one.
Related Reading
For more, see Resume Strategies for Pharma Regulatory Affairs Professionals, What Pharma Recruiters Wish Candidates Knew, Preparing for a Pharma C-Suite Interview.
Frequently Asked Questions
- Q: Why is naming an approved product insufficient?
- A: Because approvals involve large teams over years, so unspecified association is discounted heavily by readers who know how many people contribute.
- Q: What details should I include?
- A: The submission and components you owned, agency interactions you led, the pathway, the timeline, and whether the review was straightforward or contested.
- Q: Should I describe programmes that encountered difficulty?
- A: Yes; navigating a major objection, advisory committee, or required additional study demonstrates judgment under pressure, which smooth approvals do not.
- Q: Should I include failed programmes?
- A: Usually yes; experienced readers expect failures in pharmaceutical careers, and a well-described account often reads more credibly than an unbroken record of approvals.
- Q: How much detail is appropriate?
- A: Enough for a reader to assess your contribution and the judgment it required, typically a few specific lines per significant programme rather than a list of product names.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
